se of the Cyclops dry powder inhaler by patients with Parkinson's disease after inhalation instruction.

Completed

• Conditions: Parkinson; Parkinson's disease; 10028037

• Registration Number: NL-OMON55067
• Lead Sponsor: Martini Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-04-09
• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

- Diagnosed with Parkinson's disease by a nerologist;
- At least 18 years of age;
- Signed informed consent.

Exclusion Criteria

- Not able to understand inhalation instruction (within a maximum of 30
minuten).
- Previously participated in the Parkinson DPI-1, DPI-2 or DPI-3 studie (prior
knowledge of the inhalation maneuver);
- Active pulmonary disease.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is to investigate whether Parkinson*s patients are<br /><br>able to reproduce an optimal inhalation technique for the Cyclops® inhaler by<br /><br>measuring the pressure drop (kPa), breath hold time (sec.) and inhaled volume<br /><br>(L) after first and second inhalation instruction.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary study parameter is to investigate whether Parkinson*s patients<br /><br>perform the correct steps in accordance with the patient instruction card with<br /><br>the Cyclops® inhaler after first and second inhalation instruction.</p><br>